---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-25-000025"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:52:05.860766+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# LENZ Therapeutics reports $194M cash as of March 31; holds Commercial Day for LNZ100 launch preparations

## Summary
- Unaudited cash, cash equivalents and marketable securities approximately $194 million as of March 31, 2025.
- Hosting Commercial Day on April 15, 2025, focusing on potential approval and launch of LNZ100.
- Presentation includes commercialization strategies, supply chain readiness, and KOL perspectives.
- Cash figure is preliminary and subject to completion of financial closing procedures.
- No other financial results or guidance were provided in the filing.

## SEC filing metadata
- accession: 0001815776-25-000025
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000025/0001815776-25-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000025/lenz-20250415.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-25-000025
- JSON: https://secwatch.observer/filing/0001815776-25-000025.json
- Plain text: https://secwatch.observer/filing/0001815776-25-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.